NanoVibronix Inc Total Liabilities
NanoVibronix Inc total liabilities. Based on the latest financial reports, NanoVibronix Inc (NAOV) has total liabilities worth $11.92 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See NAOV days of operational coverage to measure how many days the company can operate on defensive assets alone.
Total Liabilities of NanoVibronix Inc (2011–2024)
Total liabilities of NanoVibronix Inc from 2011 to 2024. This chart illustrates how NanoVibronix Inc's total liabilities have evolved over time, based on quarterly financial data. Explore NAOV strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
NanoVibronix Inc Competitors by Total Liabilities
The table below lists competitors of NanoVibronix Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Newton Golf Company
NASDAQ:NWTG
|
USA | $5.99 Million |
|
Acurx Pharmaceuticals LLC
NASDAQ:ACXP
|
USA | $2.83 Million |
|
Sawang Export Public Company Limited
BK:SAWANG
|
Thailand | ฿37.47 Million |
|
Innity Corporation Bhd
KLSE:0147
|
Malaysia | RM39.63 Million |
|
Pure Biologics Spólka Akcyjna
WAR:PUR
|
Poland | zł20.72 Million |
|
CPPGroup Plc
F:4CV1
|
Germany | €22.06 Million |
|
AHT Syngas Technology NV
F:3SQ1
|
Germany | €6.14 Million |
|
Neola Medical AB
ST:NEOLA
|
Sweden | Skr6.86 Million |
Liability Composition Analysis (2011–2024)
This chart breaks down NanoVibronix Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see NAOV current and non-current assets.
Liquidity & Leverage Metrics
NanoVibronix Inc Total Liabilities Ratios Explained
NanoVibronix Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.86 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.28 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.22 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how NanoVibronix Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for NanoVibronix Inc (2011–2024)
The table below shows the annual total liabilities of NanoVibronix Inc from 2011 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $3.00 Million | +11.76% |
| 2023-12-31 | $2.69 Million | +1.51% |
| 2022-12-31 | $2.65 Million | +14.60% |
| 2021-12-31 | $2.31 Million | -60.43% |
| 2020-12-31 | $5.83 Million | +748.11% |
| 2019-12-31 | $688.00K | -38.41% |
| 2018-12-31 | $1.12 Million | -9.26% |
| 2017-12-31 | $1.23 Million | -58.87% |
| 2016-12-31 | $2.99 Million | +36.54% |
| 2015-12-31 | $2.19 Million | -65.42% |
| 2014-12-31 | $6.34 Million | +58.95% |
| 2013-12-31 | $3.99 Million | +82.85% |
| 2012-12-31 | $2.18 Million | +30.60% |
| 2011-12-31 | $1.67 Million | -- |
About NanoVibronix Inc
NanoVibronix, Inc., through its subsidiaries, focuses on non-invasive biological response-activating devices that target biofilm prevention, pain therapy, wound healing, and at home administration without medical professional assistance. Its product portfolio includes UroShield, an ultrasound-based product that is designed to prevent bacterial colonization and biofilm in urinary catheters, increa… Read more